Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study of the Safety and Immunogenicity of a HSV-2 Vaccine Containing Matrix M-2 Adjuvant in Individuals With Documented Genital HSV-2 Genital Infection

Next Previous
X
Search
Trial Profile

A Phase I/IIa, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study of the Safety and Immunogenicity of a HSV-2 Vaccine Containing Matrix M-2 Adjuvant in Individuals With Documented Genital HSV-2 Genital Infection

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GEN 003 (Primary) ; Matrix M
  • Indications Herpes genitalis; Herpes simplex virus type 2 infections
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Genocea Biosciences [CEASED]

    • Most Recent Events

    • 15 Sep 2016 Results assessing immune response with Gen-003 published in the Vaccine (2016).
    • 20 May 2015 Results published in the Genocea Biosciences Media Release.
    • 07 May 2015 Results data were presented at the 25th European Congress of Clinical Microbiology and Infectious Diseases in April 2015, according to a Genocea Biosciences media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top